Presentation
13 March 2024 Photobiomodulation and the microbiome: clinical trial evidence for a mechanism for modulation of symptoms of Parkinson’s disease
Author Affiliations +
Abstract
There is a close association between the gut microbiome and metabolic and neurodegenerative diseases, especially in Parkinson’s disease. The potential of photobiomodulation to alleviate motor and non-motor symptoms of Parkinson’s disease has been demonstrated in animal experiments and proof-of-concept clinical trials. We have also previously shown that PBM can alter the gut microbiome in a mouse model, case studies and in a clinical trial of Parkinson’s disease. Here we present a clinical trial documenting changes in the microbiome of Parkinson’s participants with abdominal PBM that parallel changes in the symptoms of Parkinson’s disease and the disruption of the PBM effects by antibiotics.
Conference Presentation
© (2024) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Ann Liebert, Brian Bicknell, Sharon Tilley, John Mitrofanis, and Hosen Kiat "Photobiomodulation and the microbiome: clinical trial evidence for a mechanism for modulation of symptoms of Parkinson’s disease", Proc. SPIE PC12826, Mechanisms of Photobiomodulation Therapy XVIII, PC1282601 (13 March 2024); https://doi.org/10.1117/12.3008806
Advertisement
Advertisement
KEYWORDS
Parkinson disease

Clinical trials

Modulation

Neurological disorders

Animal model studies

Animals

Bacteria

Back to Top